{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '157', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[World Health Organization', 'Globocan 2012: Lung Cancer', '[0402K4]', '2012]', 'Estimated Incidence, Mortality and', 'Prevalence Worldwide in 2012', '[Internet]. Lyon (FR): World Health', 'Organization, International Agency', 'for Research on Cancer (IARC).', 'c2014 - [updated 2014 Oct 3].', 'Available from:', 'http://globocan.iarc.fr/Pages/fact_shee', 'ts cancer.aspx', '[Yamamoto, Y., et al 2014]', 'Yamamoto Y, Matsui J, Matsushima', '[04XQ0S]', 'T, Obaishi H, Miyazaki K, Nakamura', 'K, et al. Lenvatinib, an angiogenesis', 'inhibitor targeting VEGFR/FGFR,', 'shows broad antitumor activity in', 'human tumor xenograft models', 'associated with microvessel density', 'and pericyte coverage. Vasc Cell.', '2014;6:18.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['MK-7902', 'PAGE 1', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Supplemental Statistical Analysis Plan (sSAP)', 'C', 'Confidential']['MK-7902', 'PAGE 2', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table of Contents', '1.', 'INTRODUCTION', '7', '2.', 'SUMMARY OF CHANGES', '7', '3. ANALYTICAL AND METHODOLOGICAL DETAILS FOR GLOBAL STUDY', '7', '3.1.', 'Statistical Analysis Plan Summary', '7', '3.2.', 'Responsibility for Analyses/In-house Blinding', '8', '3.3.', 'Hypotheses/Estimation', '9', '3.4.', 'Analysis Enppoints', '9', '3.4.1.', 'Efficacy Enppoints', '9', '3.4.1.1.', 'Primary Endpoints', '9', '3.4.1.2.', 'Secondary Endpoints', '9', '3.4.1.3.', 'Exploratory Endpoints', '9', '3.4.2.', 'Safety Enppoints', '9', '3.4.3.', 'Patient-reported Outcome Enppoints', '9', '3.5.', 'Analysis Populations', '11', '3.5.1.', 'Efficacy Analysis Populations', '11', '3.5.2.', 'Safety Analysis Populations', '11', '3.5.3.', 'Patient-reported Outcome Analysis Population', '12', '3.5.4.', 'Pharmacokinetic Analysis Population', '12', '3.6.', 'Statistical Methods', '12', '3.6.1.', 'Statistical Methods for Efficacy Analyses', '12', '3.6.1.1.', 'Progression-free Survival', '13', '3.6.1.2.', 'Overall Survival', '14', '3.6.1.3.', 'Objective Response Rate', '15', '3.6.1.4.', 'Duration of Response', '15', '3.6.2.', 'Statistical Methods for Safety Analyses', '15', '3.6.3.', 'Statistical Methods for Patient-reported Outcome Analyses', '17', '3.6.3.1.', 'Scoring Algorithm', '17', '3.6.3.2.', 'PRO Compliance Summary', '19', '3.6.3.3.', 'Mean Change from Baseline', '20', '3.6.3.4.', 'Time-to-True Deterioration (TTD) Analysis', '21', '3.6.3.5.', 'Overall Improvement and Overall Improvement/Stability', '22', '3.6.3.6.', 'Analysis Strategy for Key PRO Enppoints', '22', 'Confidential']\n\n###\n\n", "completion": "END"}